PTC Therapeutics Inc. (PTCT) announced Friday morning that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended renewing the conditional marketing authorization of Translarna. The drug is a treatment for nonsense mutation Duchenne muscular dystrophy in ambulatory patients five years and older.
from RTT - Before the Bell http://ift.tt/2g70qG4
via IFTTT
No comments:
Post a Comment